Source:http://linkedlifedata.com/resource/pubmed/id/20693248
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2011-4-1
|
pubmed:databankReference | |
pubmed:abstractText |
Outcome measures to assess therapeutic interventions in cystic fibrosis (CF) patients with mild lung disease are lacking. Our aim was to determine if the lung clearance index (LCI) can detect a treatment response to dornase alfa in paediatric CF patients with normal spirometry. CF patients between 6-18 yrs of age with FEV(1 )? 80% pred were eligible. In a crossover design, 17 patients received 4 weeks of dornase alfa and placebo in a randomised sequence separated by a 4-week washout period. The primary end-point was the change in LCI from dornase alfa versus placebo. A mixed model approach incorporating period-dependent baselines was used. The mean ± sd age was 10.32 ± 3.35 yrs. Dornase alfa improved LCI versus placebo (0.90 ± 1.44; p = 0.022). Forced expiratory flow at 25-75% expired volume measured by % pred and z-scores also improved in subjects on dornase alfa (6.1% ± 10.34%; p = 0.03 and 0.28 ± 0.46 z-score; p = 0.03). Dornase alfa significantly improved LCI. Therefore the LCI may be a suitable tool to assess early intervention strategies in this patient population.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1399-3003
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
37
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
806-12
|
pubmed:meshHeading |
pubmed-meshheading:20693248-Adolescent,
pubmed-meshheading:20693248-Burkholderia cepacia,
pubmed-meshheading:20693248-Child,
pubmed-meshheading:20693248-Cross-Over Studies,
pubmed-meshheading:20693248-Cystic Fibrosis,
pubmed-meshheading:20693248-Deoxyribonuclease I,
pubmed-meshheading:20693248-Female,
pubmed-meshheading:20693248-Humans,
pubmed-meshheading:20693248-Lung,
pubmed-meshheading:20693248-Male,
pubmed-meshheading:20693248-Placebos,
pubmed-meshheading:20693248-Research Design,
pubmed-meshheading:20693248-Respiratory Function Tests,
pubmed-meshheading:20693248-Spirometry,
pubmed-meshheading:20693248-Time Factors,
pubmed-meshheading:20693248-Ventilation
|
pubmed:year |
2011
|
pubmed:articleTitle |
The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis.
|
pubmed:affiliation |
Division of Respiratory Medicine, Dept of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada. reshma.amin@sickkids.ca
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|